Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Formula:C29H26FN5O3Purity:98%Color and Shape:SolidMolecular weight:511.55FGFR-IN-4
CAS:<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Formula:C24H21N7O2Color and Shape:SolidMolecular weight:439.47ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Formula:C19H22Cl2N6OSColor and Shape:SolidMolecular weight:453.39FC 11
CAS:<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Formula:C41H42F3N13O9SColor and Shape:SolidMolecular weight:949.91HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formula:C27H33N7O3Color and Shape:SolidMolecular weight:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Formula:C26H31ClN6O2Purity:98%Color and Shape:SolidMolecular weight:495.02HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Formula:C31H41N7O4Color and Shape:SolidMolecular weight:575.7HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Formula:C25H26Cl2N6O3Color and Shape:SolidMolecular weight:529.42EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Formula:C37H42N8O4Color and Shape:SolidMolecular weight:662.78Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Formula:C28H32F2N6O5Purity:99.08% - 99.38%Color and Shape:SolidMolecular weight:570.59BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Formula:C20H22Cl2N6OColor and Shape:SolidMolecular weight:433.33BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formula:C26H22ClN5O3Color and Shape:SolidMolecular weight:487.94Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Formula:C29H35Cl2N7O5Color and Shape:SolidMolecular weight:632.54BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Formula:C29H34N8O3Color and Shape:SolidMolecular weight:542.63JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Formula:C22H29N7O5Purity:98%Color and Shape:SolidMolecular weight:471.52EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Formula:C19H21N5O3Purity:97.4%Color and Shape:SolidMolecular weight:367.4BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Formula:C27H24ClF2N5O4Color and Shape:SolidMolecular weight:555.96PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66FLT3/ITD-IN-5
CAS:<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Formula:C23H25N7O2Color and Shape:SolidMolecular weight:431.49TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Formula:C26H17F4N5O4Color and Shape:SolidMolecular weight:539.44CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Formula:C18H18ClNO4S3Purity:98%Color and Shape:SolidMolecular weight:443.99CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Formula:C30H29ClN6OPurity:98%Color and Shape:SolidMolecular weight:525.04(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formula:C16H14N2O2Color and Shape:SolidMolecular weight:266.29HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Formula:C16H8F5NO4SPurity:97.99%Color and Shape:SolidMolecular weight:405.3YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formula:C30H30N4O3Purity:98%Color and Shape:SolidMolecular weight:494.5810Z-Hymenialdisine
CAS:<p>Pan kinase inhibitor</p>Formula:C11H10BrN5O2Purity:98%Color and Shape:Light Yellow SolidMolecular weight:324.13Henatinib
CAS:<p>Henatinib: orally active multi-kinase inhibitor targeting VEGFR-2, c-kit, PDGFR with antitumor effects.</p>Formula:C25H29FN4O4Color and Shape:SolidMolecular weight:468.52FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Formula:C25H24N6O2SColor and Shape:SolidMolecular weight:472.56Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Formula:C24H28N6O3SPurity:99.21% - >99.99%Color and Shape:SolidMolecular weight:480.58EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46Larixol
CAS:<p>Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for</p>Formula:C20H34O2Purity:98%Color and Shape:SolidMolecular weight:306.48Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Formula:C17H20N6O4SColor and Shape:SolidMolecular weight:404.45TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Formula:C26H27Cl2N5O2Purity:98%Color and Shape:SolidMolecular weight:512.43JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Formula:C33H34N8O2Color and Shape:SolidMolecular weight:574.68ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Formula:C30H35F3N6O3Purity:98%Color and Shape:SolidMolecular weight:584.63EGFR kinase inhibitor 1
CAS:<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Formula:C30H31N7O2Color and Shape:SolidMolecular weight:521.61BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Formula:C26H23N7O2Color and Shape:SolidMolecular weight:465.51FGFR-IN-8
CAS:<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Formula:C27H31Cl2N9O2Color and Shape:SolidMolecular weight:584.5CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Formula:C26H29N7O2Purity:99.63%Color and Shape:SolidMolecular weight:471.55MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Formula:C46H54ClFN8O8Color and Shape:SolidMolecular weight:901.42FGFR-IN-2
CAS:<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formula:C24H26N2O2Color and Shape:SolidMolecular weight:374.48EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14
